Clinical Trial News
Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
Iterum Therapeutics' NDA resubmission for oral sulopenem to treat uncomplicated urinary tract infections in adult women is accepted by the FDA, with a PDUFA action date of October 25, 2024.
U.S. FDA Acknowledges Astellas' Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date
Astellas' resubmission of the Biologics License Application (BLA) for zolbetuximab, a CLDN18.2-targeted monoclonal antibody for first-line treatment of HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma, has been acknowledged by the U.S. FDA, setting a new action date of November 9, 2024.
Related Clinical Trials:
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for Cardamyst
Milestone Pharmaceuticals announced the FDA accepted their New Drug Application for Cardamyst (etripamil) nasal spray, intended for paroxysmal supraventricular tachycardia (PSVT) management. The PDUFA target date is set for 10 months after the acceptance date. Cardamyst aims to provide a new, convenient treatment option for PSVT patients, potentially allowing self-management without medical supervision.
FDA Grants Priority Review to Roche’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
FDA grants Priority Review to Roche's inavolisib for advanced HR+/HER2- breast cancer with PIK3CA mutation, based on Phase III INAVO120 results showing significant progression-free survival benefits.
Related Clinical Trials:
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
Atara Biotherapeutics submits a Biologics License Application to the FDA for tabelecleucel (tab-cel®) as monotherapy for EBV+ PTLD patients who have received at least one prior therapy, with no FDA approved therapies in this setting. Tab-cel is an allogeneic, EBV-specific T-cell immunotherapy designed to target and eliminate EBV-infected cells, supported by pivotal data from over 430 patients. The therapy has Breakthrough Therapy and orphan drug designations, and has received marketing authorization in Europe, UK, and Switzerland under the brand name Ebvallo™.
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism
Yorvipath (palopegteriparatide) is FDA approved for hypoparathyroidism. Ascendis Pharma's review period for TransCon PTH extended to August 14, 2024.
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
Eton Pharmaceuticals submits New Drug Application to FDA for ET-400 (hydrocortisone oral solution), expecting a 10-month review for potential approval in Q1 2025.
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem
Iterum Therapeutics resubmits NDA to FDA for oral sulopenem to treat uncomplicated urinary tract infections in adult women, with data from phase 3 clinical trials demonstrating its efficacy and safety.
Abeona Therapeutics Provides Regulatory Update on Pz-cel
Abeona Therapeutics receives a Complete Response Letter from the FDA for its Biologics License Application for prademagene zamikeracel (pz-cel) due to unresolved Chemistry Manufacturing and Controls (CMC) requirements, with no deficiencies identified in clinical efficacy or safety data. The company plans to resubmit the BLA in the third quarter of 2024.
Supernus Provides Regulatory Update for SPN-830
Supernus receives a Complete Response Letter from FDA for SPN-830, an apomorphine infusion device for Parkinson’s disease, citing product quality and infusion device master file issues. No clinical safety or efficacy issues identified. Company remains committed to addressing the CRL and resubmitting the NDA.